Introduction: Human papillomavirus (HPV) is the major cause of cervical cancer, which is the second most common cancer in the world among women and is one of the major causes of cancer-related deaths in developing countries. Approximately 500.000 new cervical cancers are identified each year in the world, and close to half of them are estimated to have resulted in death. Cervical cancer is largely a preventable disease by early detection and treatment of cervical precancerous lesions with the combined use of high risk (HR) HPV DNA testing and cervical cytology test in cervical cancer screening. Prophylactic human papillomavirus vaccines, which provide primary protection against cervical cancer, have been started to be applied since 2006 with the aim of decreasing the incidence of cervical cancer and mortality. HPV vaccine has been proven to be effective in protecting against precancerous lesions by providing immunity against high risk (HR) HPV types and has been included in the routine vaccination program in many countries. The aim of this study was to investigate the prevalence and genotypes of HPV using real-time PCR test in women with abnormal cervical cytology.